Introduction/Background*The role of HIPEC in ovarian cancer has been the subject of significant debate. The publication of the OVIHIPEC trial has provided evidence to support the use of HIPEC in the interval cytoreduction setting with a complete or near partial macroscopic resection¹.

It is clear from many of the recent surgical trials in advanced and recurrent ovarian cancer that the international gynaecological oncology community has not been successful in implementing standardised surgical approaches to advanced ovarian cancer cytoreductive surgery (CRS). This includes the role, accreditation and operational protocols for HIPEC.

Methodology Our aim was to ascertain the global interest of centres practising CRS for ovarian cancer and HIPEC of contributing to an International Data Registry with a view to implement a Delphi process to address these vital issues in ovarian cancer surgery. A SurveyMonkey invitation was distributed to centres already involved within the Peritoneal Surface Oncology Group International (PSOGI) database. Invitation was voluntary and consent obtained to become involved with the registry. A short 5 question survey was initially issued to assess referral levels and accreditation requirements.

Result(s)*40 of 98 centres replied to the survey. 78% consented to become involved in an international registry. 63% of centres who replied receive between 50 - >100 referrals of ovarian cancer per year and 90% perform HIPEC in ovarian cancer. 79% (31/40) stated they had been practising CRS & HIPEC for >10 years. The number of CRS with HIPEC per year performed was <20 cases in 56% of respondents and >50 in 4%.

21% of centres held international accreditation for ovarian cancer CRS and 51% held national accreditation. Of interest was that 82% reported that no certification was required for the administration of HIPEC in their country.

Conclusion*Given the multiple reports demonstrating variations in practice across the globe we believe this could be a very important opportunity for implementing change for women with ovarian cancer. For centres that consented to participation a further survey will be issued focusing on operating standards for CRS in ovarian cancer and protocols for HIPEC administration.